

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 November 2024 (21.11.2024)



(10) International Publication Number
WO 2024/238659 A1

(51) International Patent Classification:

A61P 7/00 (2006.01) C07D 513/14 (2006.01)
A61P 7/06 (2006.01) A61K 31/5025 (2006.01)

(21) International Application Number:

PCT/US2024/029471

(22) International Filing Date:

15 May 2024 (15.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/466,552 15 May 2023 (15.05.2023) US

(71) Applicant: AGIOS PHARMACEUTICALS, INC.
[US/US]; 88 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: FANDRICK, Daniel R.; c/o Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA 02139 (US). GRENIER, Louis; 3769 Chemin Sainte-Catherine, Sherbrooke, QC J1N 3Y1 (CA). LANE, Benjamin S.; 2 Stoneway, Lynnfield, MA 01940 (US). LEE, Jaemoon; 57 Argilla Road, Andover, MA 01810 (US). LEUNG, Cheuk-Yui; c/o Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA 02139 (US). LI, Hui; 122 Madison Avenue, Arlington, MA 02474 (US). MELLOTT, Karl E.; c/o Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA 02139 (US). SIMONE, Eric; 174 Crane Neck Street, West Newbury, MA 01985 (US). Sizemore, Jacob P.; 1753 Oakdale Mist Drive, Dickinson, TX 77539 (US).

(74) Agent: DEGRAZIA, Michael J. et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: CRYSTALLINE SALTS OR AMORPHOUS FORMS OF 2-((1H-PYRAZOL-3-YL)METHYL)-6-((6-AMINOPYRIDIN-2-YL)METHYL)-4-METHYL-4,6-DIHYDRO -5H-THIAZOLO[5',4':4,5]PYRROLO[2,3-D]PYRIDAZIN-5-ONE



Compound 1. (I)

(57) Abstract: Provided herein are crystalline salts and free base forms as well as amorphous forms of the compound having the formula: (I) Also provided are pharmaceutical compositions comprising such crystalline and amorphous forms, methods for their manufacture, and uses thereof for treating various conditions such as, hemolytic anemia, sickle cell disease and MDS (very low risk MDS, low risk MDS, lower risk MDS and/or intermediate risk MDS).



WO 2024/238659 A1